JIC
TECH icon

Joel Isaacson & Co’s Bio-Techne TECH Stock Holding History

Joel Isaacson & Co’s Portfolio TECH Stock Details TECH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-232
Closed -$6K – 489
2016
Q4 		$6K Hold
232
– – ﹤0.01% 557
2016
Q3 		$6K Hold
232
– – ﹤0.01% 605
2016
Q2 		$7K Hold
232
– – ﹤0.01% 580
2016
Q1 		$5K Hold
232
– – ﹤0.01% 663
2015
Q4 		$5K Buy
+232
New +$5.29K ﹤0.01% 624

Other funds holding TECH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Joel Isaacson & Co's TECH Position: Q1 2017 in Review

Joel Isaacson & Co sold out of Bio-Techne (TECH) in Q1 2017, closing a stake of 232 shares — an estimated $6K sold.

Joel Isaacson & Co first reported a position in TECH in Q4 2015 and held it in 5 quarters. The position peaked at $7K in Q2 2016. 271 funds tracked by Wall St. Rank hold TECH as of Q1 2017.

  • Joel Isaacson & Co reported no remaining Bio-Techne position as of Q1 2017 after selling out during the quarter.
  • Joel Isaacson & Co sold 232 Bio-Techne shares in Q1 2017, an estimated $6K.
  • Joel Isaacson & Co first reported a position in Bio-Techne in Q4 2015 and held it in 5 quarters.
  • Joel Isaacson & Co's Bio-Techne position peaked at $7K in Q2 2016.
  • 271 funds tracked by Wall St. Rank held Bio-Techne as of Q1 2017.

Based on Joel Isaacson & Co's 13F filing for Q1 2017, filed 5 May 2017.